Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker D, Sato R, Strutton D, Edelsberg J, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker D, Sato R, Strutton D, Edelsberg J, et al
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Hospitalizations from flu increase with age
    People age 65+ account for 50% of flu hospitalizations.  
  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.  
  • Cost of measles much higher than vaccine
    One case of measles can cost 23 times as much as a single vaccination to prevent it.  
  • Each flu case prevented could save $60 to $4,000
    The influenza vaccination could save between $60 and $4,000 per case prevented.  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.